JCR Pharmaceuticals

JCR Pharmaceuticals

4552.T
Ashiya, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

4552.T · Stock Price

JPY 544+67 (+14.05%)
Market Cap: $423.9M

Historical price data

Market Cap: $423.9MPipeline: 11 drugs (4 Phase 3)Patents: 20Founded: 1975Employees: 938-987HQ: Ashiya, Japan

Overview

JCR Pharmaceuticals has established itself as a premier global specialty pharmaceutical company focused on high-unmet-need rare diseases, particularly lysosomal storage disorders. Its strategic advantage is anchored in the proprietary J-Brain Cargo® platform, which enables targeted delivery of biologics across the blood-brain barrier—a key differentiator in treating neurological manifestations. The company has successfully commercialized products in multiple international markets and maintains a robust clinical pipeline, driving its significant market valuation. JCR's fully integrated model, from R&D to global commercialization, combined with a strong venture spirit, positions it for sustained growth in the orphan drug space.

Lysosomal Storage DisordersNeurological DiseasesRare Genetic Diseases

Technology Platform

Proprietary J-Brain Cargo® platform utilizing receptor-mediated transcytosis to deliver biologic therapeutics across the blood-brain barrier, enabling treatment of central nervous system manifestations of disease.

Pipeline

11
11 drugs in pipeline4 in Phase 3
DrugIndicationStageWatch
JR-141 + Idursulfase + JR-141 or IdursulfaseMucopolysaccharidosis IIPhase 3
JR-141Mucopolysaccharidosis IIPhase 3
JR-141Mucopolysaccharidosis IIPhase 2/3
JR-141Mucopolysaccharidosis IIPhase 2/3
JR-141Mucopolysaccharidosis IIPhase 2

Funding History

1
IPOUndisclosed